MORPHINE SULFATE Drug Patent Profile

Which patents cover Morphine Sulfate, and what generic alternatives are available?

Morphine Sulfate is a drug marketed by Actavis Elizabeth, Anda Repository, Impax Labs Inc, Strides Pharma Intl, Teva Pharms Usa, Upsher Smith Labs, Hikma, Hospira, Hospira Inc, Icu Medical Inc, Intl Medication Sys, Specgx Llc, Watson Labs, Fresenius Kabi Usa, Ani Pharms, Chartwell Molecular, Padagis Us, Pharm Assoc, Rhodes Pharms, Sankalp Lifecare, Tris Pharma Inc, Vistapharm, Winder Labs Llc, Dava Pharms Inc, Dr Reddys Labs Sa, Epic Pharma Llc, Nesher Pharms, Novel Labs Inc, Rising, Sun Pharm Inds Ltd, Sun Pharm Industries, Alkem Labs Ltd, Ingenus Pharms Nj, and Meridian Medcl Techn. and is included in sixty-two NDAs. There are three patents protecting this drug.

This drug has twenty-four patent family members in eleven countries.

The generic ingredient in MORPHINE SULFATE is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Morphine Sulfate

A generic version of MORPHINE SULFATE was approved as morphine sulfate by HOSPIRA on September 30^th, 1992.

Summary for MORPHINE SULFATE

International Patents:	24
US Patents:	3
Applicants:	34
NDAs:	62
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MORPHINE SULFATE

Paragraph IV (Patent) Challenges for MORPHINE SULFATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MORPHABOND ER	Extended-release Tablets	morphine sulfate	15 mg, 30 mg, 60 mg and 100 mg	206544	1	2019-01-28
ARYMO ER	Extended-release Tablets	morphine sulfate	15 mg, 30 mg and 60 mg	208603	1	2017-12-29
AVINZA	Extended-release Capsules	morphine sulfate	45 mg and 75 mg	021260	1	2009-08-11
AVINZA	Extended-release Capsules	morphine sulfate	30 mg, 60 mg, 90 mg and 120 mg	021260	1	2007-06-04

US Patents and Regulatory Information for MORPHINE SULFATE

MORPHINE SULFATE is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	MORPHINE SULFATE	morphine sulfate	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	204223-001	Oct 30, 2013		RX	Yes	Yes	9,072,781		Y
Pharm Assoc	MORPHINE SULFATE	morphine sulfate	SOLUTION;ORAL	206573-001	Nov 14, 2016	AA	RX	No	No
Hikma	MORPHINE SULFATE	morphine sulfate	INJECTABLE;INJECTION	211452-001	Jan 12, 2023	AP	RX	No	No
Teva Pharms Usa	MORPHINE SULFATE	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	202718-005	Dec 29, 2014		DISCN	No	No
Sun Pharm Industries	MORPHINE SULFATE	morphine sulfate	TABLET, EXTENDED RELEASE;ORAL	205634-002	Aug 25, 2016		DISCN	No	No

International Patents for MORPHINE SULFATE

See the table below for patents covering MORPHINE SULFATE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2014140097
Japan	2016512210	注射可能なモルヒネ製剤
European Patent Office	2968132	FORMULATION DE MORPHINE INJECTABLE (INJECTABLE MORPHINE FORMULATIONS)
Japan	2016512210	注射可能なモルヒネ製剤
Australia	2014230834	Injectable morphine formulations

Investment Scenario and Fundamentals Analysis for Morphine Sulfate

Last updated: February 20, 2026

What is the current market landscape for morphine sulfate?

Morphine sulfate is a widely used opioid analgesic primarily indicated for severe pain management. It remains a standard in palliative and postoperative care, especially in hospitals and hospice settings. The global market for opioids, including morphine sulfate, was valued at approximately $5.2 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of roughly 3.9% through 2028, driven by increasing chronic pain prevalence, aging populations, and expanding healthcare access in emerging markets [1].

What are the key drivers influencing the investment potential?

1. Growing Global Pain Management Needs

Chronic pain affects an estimated 20% of adults worldwide [2]. As aging populations expand, demand for potent analgesics like morphine sulfate increases, particularly in North America and Europe.

2. Regulatory Environment and Opioid Policies

Stringent controls on opioids in North America and parts of Europe restrict supply and distribution. New markets with less restrictive policies, such as certain Asian countries, present growth opportunities.

3. Manufacturing and Supply Chain Dynamics

Major producers are often integrated pharmaceutical companies or licensed manufacturers. Patent protections are generally not applicable, as morphine sulfates are generic drugs. This results in limited price premiums but stable demand.

4. Competitive Landscape and Patent Status

Morphine sulfate is a generic product with no active patents. Investment returns depend on manufacturing efficiency, regulatory compliance, and market share rather than patent exclusivity.

5. Regulatory and Safety Risks

Increased scrutiny around opioid misuse and addiction realism can lead to supply restrictions or increased regulation, affecting sales.

What are the fundamental considerations for potential investors?

Aspect	Details	Implications
Market Size & Growth	2021 global market at $5.2 billion; CAGR 3.9%.	Stable but mature; growth driven by demand in emerging markets.
Regulatory Risk	Tight controls in developed markets; looser in some Asia-Pacific regions.	Regulatory hurdles could limit growth; strategic licensing may mitigate risks.
Manufacturing & Supply Chain	Several large generic manufacturers; low R&D costs.	Low barriers to entry; price competition impacts margins.
Pricing & Reimbursement	In developed markets, reimbursement is well-established; in emerging markets, affordability varies.	Revenue stability depends on pricing policies and healthcare infrastructure.
Legal & Ethical Factors	Rising focus on opioid misuse; potential for restriction or procurement delays.	Risks can influence distribution channels and volume.

What are the opportunities and risks?

Opportunities

• Expansion into emerging markets with less restrictive policies.
• Development of abuse-deterrent formulations.
• Partnerships with healthcare providers to improve distribution channels.

Risks

• Increased regulation and control over opioid prescriptions.
• Price erosion due to generic competition.
• Political and public perception concerns over opioid use.

How do financial metrics compare to similar generics?

Metric	Morphine Sulfate (Generic)	Typical Generic Analogs	Comments
Gross Margin	20-30%	Similar	Margins thin due to high competition.
Market Penetration	High in hospital and hospice sectors	High	Market share remains stable in developed countries.
Manufacturing Cost	Low	Similar	Costs dominated by raw materials and compliance.

What are the strategic considerations for investors?

• Focus on manufacturers with efficient supply chains and regulatory compliance.
• Monitor policy changes, especially in opioid regulation.
• Evaluate entry into emerging markets with low regulation barriers.
• Assess potential for formulation innovations, such as abuse-deterrent versions.

Closing summary

Morphine sulfate remains a critical component of pain management with a stable global demand. The market's growth hinges on expansions into less regulated regions and technological development to mitigate misuse concerns. Despite competitive pressures and regulatory risks, the non-patent status offers opportunities for manufacturers with efficient operations. Investors should consider market saturation, regulatory environment, and supply chain robustness when evaluating opportunities.

Key Takeaways

• Morphine sulfate is a mature, essential analgesic with global sales around $5.2 billion in 2021.
• Market growth driven by aging populations and expanding healthcare access, especially in Asia-Pacific.
• No patent protection; margins driven by manufacturing efficiency and market share.
• Regulatory risks impact supply and pricing, especially in North America.
• Opportunities exist through emerging markets, formulation innovation, and strategic partnerships.

FAQs

1. What is the primary growth driver for morphine sulfate?
The primary driver is increasing demand for pain management in aging populations and expanding healthcare infrastructure in emerging markets.

2. How does regulatory risk affect investment prospects?
Regulations on opioid prescribing and distribution can restrict sales, especially in North America, leading to potential revenue volatility.

3. Are there patent protections for morphine sulfate?
No; morphine sulfate is a generic drug with no active patents, leading to intense price competition.

4. What are the recent innovations in morphine sulfate formulations?
Attempts include abuse-deterrent formulations and slow-release versions, but these are not widely adopted yet.

5. Which regions present the most significant growth opportunities?
Asia-Pacific markets with less restrictive policies on opioids and expanding healthcare access offer the most substantial growth potential.

---

References

[1] MarketsandMarkets. (2022). Opioids Market by Type, Application, End-User and Region - Global Forecast to 2028.
[2] Institute of Medicine. (2011). Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research.